UK Markets closed

Freeline Therapeutics Holdings plc (FRLN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.2900-0.1200 (-8.51%)
At close: 04:00PM EST
1.3200 +0.03 (+2.33%)
After hours: 05:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.4100
Open1.3500
Bid1.3000 x 800
Ask1.3200 x 800
Day's range1.2800 - 1.4000
52-week range1.2800 - 18.4940
Volume424,767
Avg. volume914,975
Market cap46.2M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-4.0260
Earnings date09 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.00
  • Globe Newswire

    Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that on December 31, 2021, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 89,200 of the Company’s ordinary shares. The awards were granted as an ind

  • Globe Newswire

    Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

    FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced th

  • Globe Newswire

    Freeline To Participate In Conferences During January 2022

    LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that Chief Executive Officer Michael Parini is scheduled to deliver a corporate presentation at both of the following virtual conferences: H.C. Wainwright BioConnect Conference, where an on-demand w